Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Asthma
Dey L.P. and Critical Therapeutics Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for the Chronic Treatment of Asthma
October 8th, 2007
Dey, L.P., an affiliate of Merck KGaA of Darmstadt, Germany, announced that it has launched ZYFLO CR(TM) (zileuton) extended-release tablets with its marketing partner, Critical Therapeutics, Inc. (NASDAQ:CRTX). ZYFLO CR(TM) offers twice-daily, extended-release dosing for the prevention and chronic treatment of asthma in patients 12 years of age and older. "We are excited to partner with Critical Therapeutics to bring a twice-daily formulation of ZYFLO(R) (zileuton tablets) to the many patients affected by chronic asthma," said Christy Taylor, Executive Vice President, Sales, Marketing and Business Development at DEY. "Our collaboration with Critical Therapeutics and...
Source: Biotech Business Week (2007-10-08)
|
